Fampridine-SR – Treatment for Multiple Sclerosis

 
Key Data:
Drug (brand/generic)
Fampridine-SR (4-aminopyridine)
Company/licensee
Acorda Therapeutics
Therapy class
Potassium channel blocker
Product description
Selective neuronal potassium (K+) channel blocker
Current indication
Treatment of MS
Market sector
CNS
Development status
Phase III



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development